Impact of p38 mitogen-activated protein kinase inhibition on immunostimulatory properties of human 6-sulfo LacNAc dendritic cells.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Immunobiology

• Publication date

  2016-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.imbio.2015.09.012PMID 26391152
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.

  2014cited by this paper
• slanDCs selectively accumulate in carcinoma-draining lymph nodes and marginate metastatic cells

  2014cited by this paper
• Accumulation and therapeutic modulation of 6-sulfo LacNAc+ dendritic cells in multiple sclerosis

  2014cited by this paper
• p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression

  2014cited by this paper
• Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases

  2014cited by this paper
• Mitogen-activated protein kinases in innate immunity

  2013cited by this paper
• p38 mitogen-activated protein kinase (p38 MAPK)-mediated autoimmunity: lessons to learn from ANCA vasculitis and pemphigus vulgaris.

  2013cited by this paper
• Human 6-sulfo LacNAc (slan) dendritic cells have molecular and functional features of an important pro-inflammatory cell type in lupus erythematosus.

  2013cited by this paper
• The role of dendritic cells in autoimmunity

  2013cited by this paper
• Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK

  2013cited by this paper
• Novel function for the p38-MK2 signaling pathway in circulating CD1c+ (BDCA-1+) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances IL-12 whilst suppressing IL-10

  2013cited by this paper
• Cancer immunotherapy via dendritic cells

  2012cited by this paper
• Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition

  2012cited by this paper
• A clinical perspective of IL‐1β as the gatekeeper of inflammation

  2011cited by this paper
• The Bidirectional Crosstalk between Human Dendritic Cells and Natural Killer Cells

  2011cited by this paper
• Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses.

  2011cited by this paper
• Signal integration by JNK and p38 MAPK pathways in cancer development

  2009cited by this paper
• Reciprocal activating interaction between 6‐sulfo LacNAc+ dendritic cells and NK cells

  2009cited by this paper
• The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer

  2009cited by this paper
• The pivotal role of p38 and NF-kappaB signal pathways in the maturation of human monocyte-derived dendritic cells stimulated by streptococcal agent OK-432.

  2009cited by this paper
• Human natural killer cells.

  2008cited by this paper
• Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases

  2008cited by this paper
• p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.

  2008cited by this paper
• TNF‐mediated inflammatory disease

  2008cited by this paper
• dendritic-cell subsets Functional specialization of human circulating CD 16 and CD 1 c myeloid

  2007cited by this paper
• Taking dendritic cells into medicine

  2007cited by this paper
• The selectivity of protein kinase inhibitors: a further update.

  2007cited by this paper
• Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells

  2007cited by this paper
• Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells.

  2006cited by this paper
• Surface NK receptors and their ligands on tumor cells.

  2006cited by this paper
• Collaborative Action of NF-κB and p38 MAPK Is Involved in CpG DNA-Induced IFN-α and Chemokine Production in Human Plasmacytoid Dendritic Cells1

  2006cited by this paper
• Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes.

  2006cited by this paper
• Gliadin Fragments Induce Phenotypic and Functional Maturation of Human Dendritic Cells1

  2005cited by this paper
• Tumoricidal Potential of Native Blood Dendritic Cells: Direct Tumor Cell Killing and Activation of NK Cell-Mediated Cytotoxicity1

  2005cited by this paper
• The Role of the p38 Mitogen-Activated Protein Kinase, Extracellular Signal-Regulated Kinase, and Phosphoinositide-3-OH Kinase Signal Transduction Pathways in CD40 Ligand-Induced Dendritic Cell Activation and Expansion of Virus-Specific CD8+ T Cell Memory Responses 1

  2004cited by this paper
• Interleukin-12 and the regulation of innate resistance and adaptive immunity

  2003cited by this paper
• 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells.

  2002cited by this paper
• CpG‐DNA‐induced IFN‐α production involves p38 MAPK‐dependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors

  2002cited by this paper
• A Critical Role for p38 Mitogen-Activated Protein Kinase in the Maturation of Human Blood-Derived Dendritic Cells Induced by Lipopolysaccharide, TNF-α, and Contact Sensitizers

  2001cited by this paper
• Specificity and mechanism of action of some commonly used protein kinase inhibitors.

  2000cited by this paper
• Specificity and mechanism of action of some commonly used protein kinase inhibitors

  2000cited by this paper
• A novel dendritic cell population in human blood: one‐step immunomagnetic isolation by a specific mAb (M‐DC8) and in vitro priming of cytotoxic T lymphocytes

  1998cited by this paper
• Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function.

  1996cited by this paper
• The FASEB Journal express article 10.1096/fj.04-1642fje. Published online August 2, 2004. Inhibition of p38 MAP kinase- and RICK/NF-κB-signaling suppresses inflammatory bowel disease

  year unknowncited by this paper
• Kinase-Mitogen-Activated Protein Kinase Signal-Regulated Modulation of Extracellular Distinct Th Responses via Differential Agonists Instruct Dendritic Cells to Induce Cutting Edge: Different Toll-Like Receptor

  year unknowncited by this paper

• Impaired circulating myeloid CD1c+ dendritic cell function in human glioblastoma is restored by p38 inhibition – implications for the next generation of DC vaccines

  2019cites this paper
• Quantitative and functional alterations of 6-sulfo LacNac dendritic cells in multiple myeloma

  2018cites this paper
• Anaphylatoxin C5a Regulates 6-Sulfo-LacNAc Dendritic Cell Function in Human through Crosstalk with Toll-Like Receptor-Induced CREB Signaling

  2017cites this paper
• 1 ROLE OF P 38 MAPK INHIBITOR IN CONDITIONED FEAR

  2017cites this paper
• MAPK signaling pathways in eye wounds: Multifunction and cooperation.

  2017cites this paper
• Role of p38 MAPK inhibitor in conditioned fear

  2015cites this paper
• Tumor angiogenic switch determines sustained proliferative malignant transformation in tumorigenesis and overlaps with para-inflammatory phenomena

  2015cites this paper